Transdermal Scopolamine - Global Market Trajectory & Analytics

Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027

Amid the COVID-19 crisis, the global market for Transdermal Scopolamine estimated at US$368.7 Million in the year 2020, is projected to reach a revised size of US$528.5 Million by 2027, growing at a CAGR of 5.3% over the period 2020-2027.













The U.S. Market is Estimated at $108.7 Million, While China is Forecast to Grow at 4.9% CAGR

The Transdermal Scopolamine market in the U.S. is estimated at US$108.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$93.2 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Select Competitors (Total 41 Featured):

• Alchem International
• Alkaloids of Australia
• ALZA Corporation
• Baxter International Inc.
• Caleb Pharmaceuticals Inc
• Centroflora-Cms
• Fine Chemicals Corporation
• GlaxoSmithKline Plc
• Myungmoon Pharma Co. Ltd.
• Novartis AG
• Perrigo Co. Plc
• Phytex Australia